WS
TARA icon

Wedbush Securities’s Protara Therapeutics TARA Stock Holding History

Wedbush Securities’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,128
Closed -$84K – 1002
2019
Q4 		$84K Buy
5,128
+966
+23% +$11.1K 0.01% 938
2019
Q3 		$43K Buy
4,162
+1,562
+60% +$22.4K ﹤0.01% 945
2019
Q2 		$43K Buy
2,600
+1,125
+76% +$19.9K ﹤0.01% 953
2019
Q1 		$30K Buy
+1,475
New +$168K ﹤0.01% 911
2018
Q1 		– Sell
-698
Closed -$53K – 888
2017
Q4 		$53K Sell
698
-185
-21% -$14.8K 0.01% 819
2017
Q3 		$71K Sell
883
-453
-34% -$25.9K 0.01% 795
2017
Q2 		$81K Buy
1,336
+268
+25% +$15K 0.01% 781
2017
Q1 		$75K Buy
1,068
+643
+151% +$48.1K 0.01% 786
2016
Q4 		$32K Buy
+425
New +$134K ﹤0.01% 791

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Wedbush Securities's TARA Position: Q1 2020 in Review

Wedbush Securities sold out of Protara Therapeutics (TARA) in Q1 2020, closing a stake of 5,128 shares — an estimated $84K sold.

Wedbush Securities first reported a position in TARA in Q4 2016 and held it in 9 quarters. The position peaked at $84K in Q4 2019. 28 funds tracked by Wall St. Rank hold TARA as of Q1 2020.

  • Wedbush Securities reported no remaining Protara Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Wedbush Securities sold 5,128 Protara Therapeutics shares in Q1 2020, an estimated $84K.
  • Wedbush Securities first reported a position in Protara Therapeutics in Q4 2016 and held it in 9 quarters.
  • Wedbush Securities's Protara Therapeutics position peaked at $84K in Q4 2019.
  • 28 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2020.

Based on Wedbush Securities's 13F filing for Q1 2020, filed 17 Apr 2020.